Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. Articles
  3. immune rejection
Show results for
Products
Applications

Companies

News
Articles

Refine by
Date

  • This Year
  • Older

Immune Rejection Articles & Analysis

6 articles found

Research of Cell Membrane Nano Drug Delivery System and Its Application in Bionic Nanomedicine

Research of Cell Membrane Nano Drug Delivery System and Its Application in Bionic Nanomedicine

NPs, for instance, once inserted into the body will be assessed and excised by the body's innards as foreign substances that generate immune responses and toxic effects. The NP recognition by the immune system and NPs synthesis by the reticuloendothelial system are the primary barriers to nano drug delivery to organs, tissues and lesions. ...

ByCD Bioparticles


Host Cell Residual DNA: Understanding its Significance and Detection Methods

Host Cell Residual DNA: Understanding its Significance and Detection Methods

These products must not contain foreign substances, particularly host DNA, to avoid immune rejection and potential threats to life safety. Regulatory agencies worldwide have imposed strict limits on the amount of rcDNA, and various pharmacopoeias have outlined several reliable methods for residual DNA quantification, including threshold methods, hybridization ...

ByCreative Proteomics


What is FGL2?

What is FGL2?

As a protein molecule related to chronic inflammation and immune injury, FGL2 can also promote the occurrence and development of tumors. ...

ByCreative Diagnostics


SIG-005: Novel Encapsulated Non-Viral Cell-Based Therapy for MPS-1

SIG-005: Novel Encapsulated Non-Viral Cell-Based Therapy for MPS-1

HYPOTHESIS: sustained therapeutic effect could be achieved by administration of IDUA-secreting allogeneic human cells shielded within spheres designed to avoid immune rejection and pericapsular fibrotic overgrowth ...

ByEli Lilly and Company


Development of a Novel Encapsulated Non-Viral Cell-Based, BBB-Penetrant Therapy for MPS I

Development of a Novel Encapsulated Non-Viral Cell-Based, BBB-Penetrant Therapy for MPS I

MPS I is caused by deficiency of the lysosomal enzyme a-L-iduronidase (IDUA) leading to GAG accumulation in multiple tissues and organs This accumulation results in a complex array of progressive, multi-systemic pathologies, including CNS manifestations Approved therapies include enzyme replacement therapy (ERT), with chaperone and gene therapies under investigation Treatment with approved ...

ByEli Lilly and Company


The Reality of Diabetes Reversal

The Reality of Diabetes Reversal

One issue with this treatment is the widespread potential for “immune rejection” where the body sees the islets as foreign and tries to destroy them. ...

ByAnalox Instruments Ltd

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT